Back to Search
JENNIFER GRANDIS, MD
MD
Specialist
NPI: 1497729735IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD044455E(PA)
CMS Specialties
PrimaryOTOLARYNGOLOGY
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 1987
Research & Publications (20)
Targeting angiogenesis from premalignancy to metastases.
PMID 19336719·Cancer Prev Res (Phila)·2009
6-review
Advances and challenges in aerodigestive epithelial cancer: meeting summary and research opportunities.
PMID 17686829·Cancer Res·2007
7-preclinical
Established and emerging concepts in epidermal growth factor receptor biology.
PMID 17848285·Int J Radiat Oncol Biol Phys·2007
8-other
Research education and training in otolaryngology: meeting summary and research opportunities.
PMID 16949965·Otolaryngol Head Neck Surg·2006
8-other
The gender gap in a surgical subspecialty: analysis of career and lifestyle factors.
PMID 15210549·Arch Otolaryngol Head Neck Surg·2004
8-other
Signaling through the epidermal growth factor receptor during the development of malignancy.
PMID 15056497·Pharmacol Ther·2004
6-review
Head and neck cancer: meeting summary and research opportunities.
PMID 15520225·Cancer Res·2004
8-other
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
PMID 10760290·Proc Natl Acad Sci U S A·2000
7-preclinical
Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
PMID 10914726·Clin Cancer Res·2000
8-other
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
PMID 19470725·Clin Cancer Res·2009
7-preclinical
STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro.
PMID 19588483·Int J Cancer·2009
8-other
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
PMID 19638453·Mol Cancer Ther·2009
8-other
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
PMID 19421143·Oncogene·2009
7-preclinical
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
PMID 19319529·Cancer Immunol Immunother·2009
8-other
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
PMID 19246337·Mol Pharmacol·2009
8-other
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.
PMID 19636423·J Oncol·2009
8-other
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
PMID 19204206·J Clin Oncol·2009
3-trial
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
PMID 19028347·Semin Radiat Oncol·2009
6-review
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells.
PMID 18832597·FASEB J·2009
8-other
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
PMID 19464819·Int J Radiat Oncol Biol Phys·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 LOTHROP ST, SUITE 300, EYE & EAR INSTITUTE
PITTSBURGH, PA 15213 - Phone
- (412) 647-2100
Quick Facts
- NPI
- 1497729735
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile